)5$h߄I=t)IC@h馝yR=$Ll4iiQoDd}FG?M9iaoDd}FGS-"M!°aO$H+NvvFGik!NwvdD -
综上所述,敲低CML大鼠移植细胞内EZH2,可有效降低骨髓和脾脏内CML细胞不同亚群细胞比例,其作用机制可能和上调PI3K/AKT/mTOR信号通路内各蛋白表达有关。
[参考文献]
[1] 黎韵瑶,陈纯.急性髓细胞白血病甲基化改变及临床治疗的研究进展[J].国际输血及血液学杂志,2018,41(1):30-36.
[2] 程艳红,徐修才.慢性髓细胞性白血病耐药机制的研究进展[J].实用医学杂志,2018,34(11):521-524.
[3] Zhou J,Nie D,Li J,et al. PTEN is fundamental for elimination of leukemia stem cells mediated by GSK126 targeting EZH2 in chronic myelogenous leukemia[J]. Clinical Cancer Research,2018,24(1):17-22.
[4] 刘杨,余康捷,王哲,等.组蛋白甲基转移酶EZH2和MLL2在弥漫大B细胞淋巴瘤中的最新研究进展[J].现代肿瘤医学,2018,26(10):1634-1638.
[5] G?llner S,Oellerich T,Agrawalsingh S,et al.Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia[J]. Nature Medi-cine,2017,23(1):69-78.
[6] 吴家林,陈香宇,田钦.急性病毒感染条件下组蛋白甲基化转移酶EZH2对CD4+T细胞mTOR信号通路的影响[J].免疫学杂志,2019,7(4):304-308.
[7] Min C,Moore N,Shearstone JR,et al. Selective inhibitors of histone deacetylases 1 and 2 synergize with azacitidine in acute myeloid leukemia[J]. Plos One,2017,12(1):128-132.
[8] 徐金升,高少輝,白亚玲,等.干扰组蛋白赖氨酸甲基转移酶SET8对肾透明细胞癌786-O细胞增殖的影响[J].中华肿瘤防治杂志,2017,24(8):524-528.
[9] Zhang G,Zhang L,Yang X,et al. High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation[J].Annals of Hematology,2018,11(8):1-7.
[10] Fujita S,Honma D,Adachi N,et al.Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia[J].Leukemia,2018,32(4):855-859.
[11] 王珍珍,邱少伟,王建祥.治疗急性髓细胞白血病新药的研究进展[J].国际输血及血液学杂志,2017,40(2):169-173.
[12] Bapat A,Keita N,Martelly W,et al. Myeloid disease mutations of splicing factor SRSF2 cause G2-M arrest and skewed differentiation of human hematopoietic stem and progenitor cells[J]. Stem Cells,2018,36(11):204-208.
[13] 李正发,刘伟,杜云云,等.异基因造血干细胞移植治疗慢性髓细胞性白血病监测染色体核型及融合基因表达[J].中国组织工程研究,2017,21(29):4691-4696.
[14] Kandarpa M,Wu YM,Dan R,et al. Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis[J]. American Journal of Hematology,2017,92(6):555-559.
[15] 宋磊,徐鑫,赵瑶,等.组蛋白去甲基化酶KDM3B在急性髓系白血病中的靶基因鉴定[J].现代肿瘤医学,2018, 26(8):307-311.
[16] 张玉峰,刘红玉.药物基因组学在慢性髓细胞白血病靶向治疗中的研究进展[J].国际输血及血液学杂志,2017, 40(40):425-428.
[17] Najafabadi MM,Shamsasenjan K,Akbarzadehalaleh P. Angiogenesis status in patients with acute myeloid leukemia:From diagnosis to post-hematopoietic stem cell transplantation[J]. International Journal of Organ Tran-splantation Medicine,2017,8(2):57-67.
[18] Yu T,Wang Y,Hu Q,et al. The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells[J]. Oncotarget, 2017, 8(58):98348-98359.
[19] Razmkhah F,Soleimani M,Mehrabani D,et al. Leukemia microvesicles affect healthy hematopoietic stem cells[J]. Tumour Biol,2017,39(2):2234-2238.
[20] Xu DD,Ying W,Zhou P J,et al. The IGF2/IGF1R/Nanog signaling pathway regulates the proliferation of acute myeloid leukemia stem cells[J]. Frontiers in Pharmacology,2018,9(5):687-690.
(收稿日期:2019-05-27)